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Objective: Management of pain, agitation and delirium (PAD) remains to be a true challenge in critically ill patients. The pharmacolog-
ical proprieties of dexmedetomidine (DEX) make it an ideal candidate drug for light and cooperative sedation, but many practical ques-
tions remain unanswered. This structured consensus from 17 intensivists well experienced on PAD management and DEX use provides 
indications for the appropriate use of DEX in clinical practice.
Methods: A modified RAND/UCLA appropriateness method was used. In four predefined patient populations, the clinical scenarios do 
not properly cope by the current recommended pharmacological strategies (except DEX), and the possible advantages of DEX use were 
identified and voted for agreement, after reviewing literature data.
Results: Three scenarios in medical patients, five scenarios in patients with acute respiratory failure undergoing non-invasive ventilation, 
three scenarios in patients with cardiac surgery in the early postoperative period and three scenarios in patients with overt delirium were 
identified as challenging with the current PAD strategies. In these scenarios, the use of DEX was voted as potentially useful by most of the 
panellists owing to its specific pharmacological characteristics, such as conservation of cognitive function, lack of effects on the respiratory 
drive, low induction of delirium and analgesia effects.
Conclusion: DEX might be considered as a first-line sedative in different scenarios even though conclusive data on its benefits are still 
lacking.






Invasive procedures, such as tracheal intubation and me-chanical ventilation, anxiety and difficulties in commu-nication commonly cause pain, agitation and delirium 
(PAD) in critically ill patients admitted to the intensive 
care unit (ICU) (1). The management of PAD remains 
to be a true challenge despite significant recent scientific 
advances, particularly in specific populations and settings 
with elderly, children and patients with shock, brain in-
jury or substance abuse (2) In recent years, several studies 
showed that deep sedation, even for short periods, com-
pared to light sedation is closely associated to prolonged 
mechanical ventilation and ICU stay, increased incidence 
of delirium and high risk of mortality (3-5). Moreover, 
sedation protocol based mainly on the use of benzodiaze-
pines appears to be related to a higher risk of bad clinical 
outcome compared to strategies based on propofol (6-10). 
In fact, the recent evidence-based guidelines strongly sup-
port the use of a light sedation strategy and suggest the use 
of drugs (i.e., propofol and dexmedetomidine (DEX)) that 
may reduce delirium occurrence (6, 11, 12). Moreover, for 
the optimisation of the level and quality of sedation, differ-
ent strategies have been proposed as daily interruption (4), 
nursing-implemented sedation scale (13, 14) and delirium 
control to avoid hypnotic drugs (13).
DEX is an agonist of α2-adrenergic receptors that acts on the 
‘locus coeruleus’, exerting sedative, analgesia and anti-shiver-
ing effects without interference on the central and peripheral 
respiratory drive. Its proprieties, combined with an excellent 
safety profile at the appropriate doses (15), make DEX ide-
al for light and cooperative sedation in critically ill patients 
(16). Although several clinical experiences have reported the 
possible advantages provided by DEX in different settings, 
scientific data are still weak, and many questions remained 
unanswered regarding its use in daily practice. Who is the 
patient/scenario that benefits the most? What is the correct 
dose approach in different patients?
The present study reports the results of a structured consensus 
of 17 intensivists well experienced on PAD management and 
DEX use aimed to identify and analyse the unsolved ques-
tions and to provide practical indications for the appropriate 
use of DEX in clinical practice.
Methods
A modified RAND/UCLA appropriateness method was used 
(17). RAND/UCLA is a structured process for integrating 
evidence from the scientific literature with experts’ clinical 
judgement to produce explicit criteria to determine the ap-
propriateness of specific procedures when high-quality and 
definitive evidence (usually from large randomised controlled 
trials) are missing.
Two moderators (GM and LT) selected 15 panellists based 
on their experience in the use of DEX for management of 
sedation and delirium in critically ill patients. All panellists 
were intensivists with >10 years of clinical experience from 
medical, surgical, mixed and cardiac surgery ICUs of tertiary 
hospitals in Italy.
In the first structured meeting led by the two moderators 
at which all panellists were present, the panellists were in-
structed on the RAND/UCLA method, particularly on the 
definition of clinical scenarios and rating procedures. After 
an initial discussion on the main difficulties in PAD man-
agement and the clinical experience on the use of DEX, in 
accordance with the evidence-based guidelines that recom-
mend a different approach to PAD in specific populations 
and settings, the panellists defined the clinical scenarios into 
four different subgroups of critically ill patients: (1) medical 
patients, (2) patients with acute respiratory failure candidates 
to non-invasive ventilation (NIV), (3) patients with cardiac 
surgery in the early postoperative period and (4) patients with 
overt delirium. Then, for each patient subgroup, the panel-
lists were asked to identify clinical scenarios that do not prop-
erly cope by using the current recommended pharmacologi-
cal and non-pharmacological PAD strategies (except DEX), 
and the possible advantages allowed by the use of DEX in 
those scenarios. Moreover, the group identified specific clin-
ical scenarios where the use of DEX is not recommended or 
is inappropriate.
Two or three panellists were assigned the task of reviewing 
literature data, particularly evidence-based documents and 
the new clinical trials, and presenting their findings at a sec-
ond structured meeting held 3 months later for each clinical 
scenario. During this meeting, literature data were reviewed 
and discussed by the entire group, and if any controversies 
occurred, the list of clinical scenarios was better redefined to 
avoid uncertainness in the rating procedures. All the literature 
material was readily available at any time for all the panellists. 
Each member of the panel completed the first round of rat-
ing within 6 weeks after the meeting using a specific rating 
sheet. The panellists rated each clinical scenario as ‘appropri-
ate’, ‘inappropriate’ or ‘uncertain’ on a scale of 1 to 9 points, 
with 1=completely inappropriate and 9=fully appropriate (9). 
The ratings were analysed by the moderators to identify the 
scenarios with disagreement (as discussed below). In a third 
meeting, summaries of the group’s overall ratings of the sce-
narios with disagreements were presented, and the scenarios 
were adequately discussed. Then, the panellists individually 
rerated the scenarios, and their rating sheets were collected 
by the moderators. With regard to the potential benefits of 
DEX use, which were not clearly specified, the panellists were 
invited to focus on the expected effects of DEX on the length 
of mechanical ventilation, ICU stay and occurrence of deliri-
um and not to consider the cost in making their judgements.
The median of the ratings of all panellists was calculated, and 
we defined the inappropriate scenario with a median value 
from 1 to 3 (4-6=uncertain and 7-9=appropriate) for each 
Pasero et al. Dexmedetomidine Use in Practice
177
scenario. ‘Disagreement’ for each scenario was defined when 
>5 panellists rated outside the 3-point region (1-3, 4-6 and 
7-9) containing the median (14).
Results
The challenging clinical scenarios in PAD management and 
rationale for the use of DEX are shown in Tables 1 and 2.
In the four predefined subgroups of ICU patients, 17 panel-
lists identified 14 clinical scenarios with difficulties in PAD 
management. Of the 14 scenarios, three were in medical pa-
tients, five in patients with acute respiratory failure candi-
dates to NIV, three in patients with cardiac surgery in the 
early postoperative period and three in patients with overt 
delirium (Table 1).
Medical patients
All panellists agreed that in patients with mechanical venti-
lation lasting >72 h, weaning from sedation may be difficult. 
Similarly, for the large majority of the panellists, PAD man-
agement may be complicated in patients with underlying de-
generative cerebral diseases and with substance abuse. Specif-
ic DEX pharmacokinetic/pharmacodynamic characteristics 
may be really helpful for weaning from prolonged sedation, 
management of patients with underlying cerebral diseases 
and substance abuse. In fact, DEX does not appear to impair 
the peripheral and central respiratory drive, facilitates patient 
interaction with the environment, improves the quality of 
sleep and may reduce neurovegetative response.
Patients undergoing NIV
There was an excellent agreement that current sedatives exert 
a dose-dependent respiratory drive depression. Thus, difficul-
ties in maintaining light sedation still has been considered to 
be problematic in many patients undergoing NIV with high 
risk of oversedation requiring special attention for the upper 
airway control. In addition, the intolerance to NIV interfaces 
in very agitated patients (Richmond Agitation-Sedation Scale 
(RASS) >3) or patients with delirium, and sleep disturbances 
during NIV remain unsolved issues for the majority of the 
panellists. DEX may be a valid option for patients undergo-
ing NIV because, in addition to the maintenance of respira-
tory drive, it appears to provide a better upper airway control, 
reducing the occurrence of bronchospasm and the risk of over 
sedation.
Patients with post-cardiac surgery
One panellist who had no experience in this setting did not 
participate in the scenario identification and ballot. Similar to 
the patients undergoing NIV, the panellists identified prob-
lematic dose-dependent respiratory depression of the current 
sedatives. An issue was also raised on the lack of analgesia 
Table 1. Clinical scenarios do not properly cope by the current pain, agitation and delirium strategies (without 
considering dexmedetomidine) identified by the panellists and subdivided into four subgroups of critically ill 
patients. The ballot for each scenario is also reported
 Appropriate Inappropriate Uncertain
Medical patients   
Weaning from sedation in patients with prolonged mechanical ventilation (>72 h) 17 0 0
Underlying degenerative cerebral diseases 15 1 1
Weaning from sedation in patients with substance abuse 13 0 4
Patients undergoing NIV   
Dose-dependent respiratory drive depression induced by current sedatives 16 1 0
Airway control in sedated patients undergoing NIV 14 1 2
Risk of oversedation and difficulties in obtaining a light sedation level 16 1 0
Sleep disturbances 14 1 2
Intolerance to NIV in patients with agitation/delirium 17 0 0
Patients with post-cardiac surgery   
Dose-dependent respiratory drive depression induced by current sedatives 15 1 0
Propofol and benzodiazepines show no analgesia properties 14 0 2
Gastrointestinal paralysis due to opioids 13 0 3
Patients with delirium   
Risk of oversedation and difficulties in obtaining a light sedation level 17 0 0
Use of benzodiazepines may increase the incidence of delirium 17 0 0
Practical use of antipsychotics and anxiolytics for agitation and delirium 16 0 1
NIV: non invasive ventilation
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properties of propofol and midazolam and on the possible 
negative effects of opioids on gastroenteric motility. The mild 
analgesia effect of DEX was considered relevant in this popu-
lation as well as its low impact on gastroenteric atony.
Patients with delirium
In patients with delirium, the panellists highlighted the diffi-
culties in obtaining and maintaining a strategy of light seda-
tion and cooperation, with risk of oversedation. Moreover, all 
the panellists recognise the appropriate use of antipsychotics 
in delirious critically ill patients as a true challenge. The pan-
ellists indicated that the low risk of oversedation, reduction 
of delirium time and preservation of cognitive function make 
DEX a useful option in patients with delirium in combina-
tion with other antipsychotics.
Inappropriate use of DEX
The panellists considered the inappropriate use of DEX as an 
induction agent for tracheal intubation, for the treatment of 
status epilepticus, for sedation during muscle relaxants use 
and in patients with refractory hemodynamic instability and 
requiring deep sedation (Table 3). Only 71% of the experts 
Table 2. The rationale for the use of dexmedetomidine in the clinical scenarios does not properly cope by the 
current pain, agitation and delirium strategies. The ballot for each rationale is also reported
Clinical scenarios Rationale for dexmedetomidine use Appropriate Inappropriate Uncertain
Medical patients    
Weaning from sedation in patients with DEX does not impair respiratory drive 17 0 0
prolonged mechanical ventilation (>72 h) DEX improves the comfort and interaction 17 0 0 
 with the environment 
Underlying degenerative cerebral diseases DEX reduces the occurrence of delirium and 17 0 0 
 exerts protective effects on cognitive function 
Weaning from sedation in patients  DEX reduces neurovegetative response to stress 15 0 2 
with substance abuse 
Patients undergoing NIV    
Dose-dependent respiratory drive  DEX does not impair respiratory drive 17 0 0 
depression induced by current sedatives 
Airway control in sedated patients  DEX allows better upper airway protection and 17 0 0 
undergoing NIV reduces the occurrence of bronchoconstriction  
Risk of oversedation and difficulties  DEX pharmacodynamics reduces the risk of 14 0 3 
in obtaining a light sedation level oversedation 
Sleep disturbances DEX improves sleep quality, mimicking natural  16 0 1 
 electroencephalography pattern 
Intolerance to NIV in patients with  DEX improves the comfort and interaction with 17 0 0 
agitation/delirium the environment 
Patients with post-cardiac surgery    
Dose-dependent respiratory drive  DEX does not impair respiratory drive 17 0 0 
depression induced by current sedatives 
Propofol and benzodiazepines show  DEX may exert synergic analgesia effects 16 0 0 
no analgesia properties 
Gastrointestinal paralysis due to  DEX may reduce the occurrence of gastrointestinal 13 0 3 
opioid use paralysis due to opioid use 
Patients with delirium    
Risk of oversedation and difficulties  DEX does not impair respiratory drive 17 0 0
in obtaining a light sedation level
 DEX improves the comfort and interaction  15 0 2 
 with the environment 
Use of benzodiazepines may increase  DEX reduces the occurrence of delirium and 17 0 0 
the incidence of delirium exerts protective effects on cognitive function 
Practical use of antipsychotics and  DEX in combination with antipsychotics  15 0 2 
anxiolytics for agitation and delirium preserves cognitive function and reduces the  
 occurrence of delirium 
 DEX allows reduction of other antipsychotics 14 1 2
DEX: dexmedetomidine; NIV: non invasive ventilation
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considered DEX to be inappropriate in patients with trau-
matic brain injury and after neurosurgery. Similarly, only 
59% of the experts did not indicate the use of DEX for de-
lirium prophylaxis in specific populations. A wide difference 
in opinions also occurred on the European Medical Agency 
restriction to use DEX only in patients admitted to the ICU, 
with 60% of the panellists who were uncertain or in disagree-
ment with this restriction.
Discussion
This structured consensus by experts from 17 Italian ICUs 
showed that PAD management in critically ill patients is still 
problematic in many circumstances, and that DEX may repre-
sent a valuable option due to its peculiar pharmacological char-
acteristics. Moreover, the experts agreed that DEX should be 
used with caution in specific patients, but it may be considered 
for use even outside the ICU and for patients with limited data 
available, for instance in patients with cerebral dysfunction.
Weaning from prolonged sedation may be a challenging task, 
particularly in patients undergoing invasive mechanical venti-
lation for acute respiratory failure or cerebral dysfunction (e.g., 
cerebral stroke or traumatic brain injury). In these settings, 
deep sedation is usually achieved immediately after ICU admis-
sion and maintained for several days to control discomfort and 
facilitate mechanical ventilation. Moreover, in these patients, 
daily interruption of deep sedation is impracticable and rarely 
applied, and deep sedation usually continues until clinical im-
provement or weaning from the mechanical ventilation (18). 
Recently, different authors showed that a light sedation strategy 
with DEX (RASS between −2 and 1) appears to provide good 
tolerance of the endotracheal tube and to reduce the incidence 
of agitation, delirium and need of physical restraints (19, 20). 
In the difficult-to-wean patients, the use of DEX, compared 
to other agents, might improve patient-ventilator asynchrony 
and increase the success of weaning from the mechanical ven-
tilation because it does not interfere with the respiratory drive 
(21-23). However, it is important to underline that the use of 
DEX did not significantly reduce the duration of mechanical 
ventilation in medical patients (19, 20, 22, 24).
During NIV, patient agitation and intolerance to interface are 
the main reasons for failure, but very few data are available in 
the literature (25). For instance, the recent systematic review by 
the Cochrane group (26) on the use of NIV as weaning strat-
egy from invasive mechanical ventilation showed that none of 
the studies included, but one, reported standardised sedation 
protocols, and the use of sedation was described only in four 
trials (27-30). A survey on sedation practice in patients under-
going NIV for acute respiratory failure indicated that <25% 
of the patients received sedation, usually with benzodiazepine 
(33%) or opioid alone (29%) (31). Moreover, it should be kept 
in mind that the majority of sedatives interfere with the respi-
ratory drive and might reduce the control of the upper airways 
with an increased risk of inhalation and reintubation (32). Al-
though data on the use of DEX during NIV are still insuffi-
cient for definitive conclusions (33-35), the panellists support 
the use of DEX as a first-line sedative during NIV owing to its 
pharmacodynamic characteristics that offer significant advan-
tages compared to other sedatives in terms of respiratory drive 
conservation and protection of the upper airways.
Several recent studies and two meta-analyses indicated that 
DEX may reduce the time to extubation in patients recovering 
from cardiac surgery especially those undergoing pump cor-
onary artery bypass grafts (36-40). Propofol and midazolam, 
which are currently used in the postoperative period in patients 
with cardiac surgery, do not exert any analgesia effect, and thus 
opioids should be combined to control postoperative and pro-
cedural pain. It is well known that the use of opioids induces 
impairment of intestinal motility with risk of postoperative 
ileus (41). In this context, the analgesia proprieties of DEX 
may be advantageous in decreasing the opioid dose. In fact, it 
has been shown that the use of DEX allows a satisfactory pain 
control with lower dose of opioids and appears to be associated 
with a lower risk of postoperative ileus (42).
Table 3. Inappropriate use of dexmedetomidine
Clinical scenarios Appropriate Inappropriate Uncertain
DEX should be not used for sedation in patients outside the ICU 7 5 5
DEX should be not used as sole induction agent for tracheal intubation 17 0 0
DEX should be not used for sedation during muscle relaxants use 17 0 0
DEX should be not used in patients requiring deep sedation 14 1 2
DEX should be not used in patients with refractory hemodynamic instability 17 0 0
DEX should be not used in patients with severe neurological diseases  12 0 5 
(e.g., traumatic brain injury and neurosurgery) 
DEX should be not used during pregnancy and breast feeding 17 0 0
DEX should be not used as the sole agent for the treatment of refractory status epilepticus 17 0 0
DEX should be not used for delirium prophylaxis 10 4 3
DEX: dexmedetomidine; ICU: intensive care unit
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Delirium often complicates the patient management and 
outcome with prolonged ICU and hospital length of stay and 
increased mortality (43-45). Most of the clinicians recognised 
that in patients with delirium, the management of symptoms 
and agitation is often intricate. For instance, the use of ben-
zodiazepines in critically ill patients is related to a high risk 
of delirium even though the true mechanisms are still uncer-
tain (46-51).  Additionally, it should be kept in mind that 
the withdrawal of benzodiazepines is commonly associated to 
delirium development (52). The use of haloperidol or other 
first generation of antipsychotics led to conflicting results. In 
fact, many studies reported life-threatening collateral effects, 
such as third degree atrioventricular block, ventricular tachy-
cardia and neuroleptic malignant syndrome, with the use of 
high doses of haloperidol to control the symptoms of patients 
with delirium (53, 54). A second generation of atypical neu-
roleptic drugs was recently introduced with good results even 
though it still inconclusive (55, 56). The difficulties in man-
aging patients with delirium led the research toward the iden-
tification of causative factors and to develop specific strategies 
for preventing its occurrence. Among these strategies, the in-
troduction of DEX in light sedation protocols was associated 
with a significant reduction in delirium occurrence and pres-
ervation of cognitive functions (6, 15, 19). Although the true 
mechanisms have not been elucidated, the more physiologi-
cal sleep pattern provided by DEX with the restoration of the 
awake-sleep rhythm associated to light and cooperative seda-
tion may justify the difference with other sedatives in the risk 
of delirium (57, 58). Unfortunately, two recent multicentre 
randomised trials on patients with surgery (404 patients) and 
sepsis requiring mechanical ventilation (201 patients) did not 
show any benefit by using DEX in reducing delirium, cogni-
tive dysfunction, mortality and ventilator free-days (59, 60).
Few promising data on the role of DEX in treating agitated delir-
ium are available. A recent trial showed that DEX may be useful 
as a rescue drug for treating agitation due to delirium refractory 
to haloperidol in ICU non-intubated patients (61). Similarly, a 
multinational, randomised, double-blind study (DahLIA trial), 
including mechanically ventilated patients in whom extubation 
was considered inappropriate owing to the severity of agitation 
and delirium, demonstrating DEX compared to the placebo 
group provides a significant decrease of mechanical ventilation 
time and of ICU and hospital length of stay (62).
With regard to inappropriate use, the panellists agreed that 
DEX should be avoided or used with caution in contexts 
with limited experience of use, for instance in patients with 
refractory hemodynamic instability or with severe acute 
neurological injury. On the contrary, the limitation of use 
only in ICU patients was considered too restrictive, and the 
panellists support the use of DEX outside the ICU for light 
sedation during procedures, such as endoscopy and transcu-
taneous cardiac procedures, because the lack of effects on the 
respiratory drive (as discussed above) facilitates spontaneous 
breathing during the procedures.
Conclusion
Many controversies and uncertainties remain to be elucidat-
ed for the appropriate and effective management of PAD 
in critically ill patients. Avoiding prolonged deep sedation 
combined with personalised approach and use of non-phar-
macological strategies appear to be the keys for further im-
provement. With this aim, the favourable pharmacological 
characteristics make DEX a useful option as a first-line seda-
tive particularly in challenging scenarios, such as weaning pa-
tients from prolonged sedation or patients undergoing NIV 
for acute respiratory failure. The promising initial results and 
the positive clinical experiences support the use of DEX in 
these situations even though conclusive data on its benefits 
are lacking, and many practical questions regarding its use 
still remained unanswered.
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